First cell therapy for solid tumours heads to the clinic: what it means for cancer treatment.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Bibliometric analysis of single-cell RNA sequencing in tumor microenvironment.Discover oncology · 2026
   Review
2. Dual role of IFNγ in reprogramming the undifferentiated pleomorphic sarcoma cell line JBT19 towards cytotoxic chemotherapy and antitumor immunity.Oncology letters · 2026
   Article
3. αPD-1-conjugated acid-cleavable nanodrugs overcomes cellular immunotherapy barriers in pancreatic tumors.Nature communications · 2025
   Article
4. Addressing clinical needs in NSCLC immunotherapy: Mechanisms of resistance and promising combination strategies.Cell reports. Medicine · 2025
   Review
5. Exploration of the role of immune cells and cell therapy in hepatocellular carcinoma.Frontiers in immunology · 2025
   Review
6. Targeting Cancer: Microenvironment and Immunotherapy Innovations.International journal of molecular sciences · 2024
   Review
7. Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer.Cancer letters · 2024
   Review
8. High-throughput screening for optimizing adoptive T cell therapies.Experimental hematology & oncology · 2024
   Review
9. A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives.Journal of immunotherapy and precision oncology · 2024
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as